Lupin’s novel drug program seems to be on track. They concluded their third milestone payment ($50 mn for MEK product with Boehringer). Here is a broad timeline of the major developments thus far.
- NCE program is focused on oncology, immunology, and metabolic disorders
- MALT1 AbbVie partnership (Q3FY19): Received $30 mn upfront, milestone payments upto $947 mn + royalty on sales
- MEK Boehringer partnership:
o MEK inhibitor compound is planned for clinical development in combination with Boehringer Ingelheim’s KRAS inhibitor pipeline to address KRAS-driven cancers
o 04-09-2021: Received $20 mn upfront, milestone payments up to $700 mn + double digit royalty on sales
o 27-05-2021: Received $50 mn milestone payment
Disclosure: Invested (position size here)